|
IMP: Board Resolution No.02 _ 03 Jan 2017 The BODs of Imexpharm Corporation announced Resolution No.02 dated January 03, 2017 as follows:
Article 1: Approving the estimated business result in 2016:
- Total revenue: 1,005 billion dongs, equivalent to 91% of plan for 2016
- Profit before tax & extract from Science and Technology Fund: 137 billion dongs, equivalent to 98% of plan for 2016
Article 2: Approving plan for business production in 2017:
- Total revenue: 1,260 billion dongs, increase 25% compare with the 2016
- Profit before tax & extract from Science and Technology Fund: 160 billion dongs, increase 17% compare with the 2016
Article 3: Approving the issuance of shares under ESOP document to submit to the State Securities Committee.
Article 4: Approving the cooperation with Baoviet Securities Joint Stock Company to the issuance underwriting of shares to implement right for domestic existing shareholders.
Article 5: Approving the investment in home working for experts and key staff.
Article 6: Approving the appointment of Ms. Le Van Nha Phuong as Deputy CEO of IMP.
Article 7: This Resolution will be effective from January 03, 2017. HOSE
|
